Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
CGBJSGAELGCMKE
|
9.5 | IC50 | 11 | — | |
FIUDAJSOKHKCEH
|
9.5 | IC50 | 2 | — | |
JUVAOVBSTMBYPN
|
9.5 | IC50 | 5 | — | |
KARZWASGGWJISD
|
9.5 | Ki | 2 | — | |
LQBQQAXIISEIGM
|
9.5 | IC50 | 2 | — | |
MSLMLOUWBRFGOO
|
9.5 | IC50 | 3 | — | |
PNVCJWPREJZASR
|
9.5 | IC50 | 3 | — | |
QDCAVNQUDWDLDZ
|
9.5 | IC50 | 3 | — | |
UDAWZLGMHSEQAG
|
9.5 | IC50 | 2 | — | |
YKPMNBJYASHWAN
|
9.5 | IC50 | 5 | — | |
ZZCOJCXQAHQFAH
|
9.5 | IC50 | 2 | — | |
ITXYPAQDIOJYSR
|
9.5 | IC50 | 3 | — | |
DCWBQVATVGTHLS
|
9.5 | IC50 | 3 | — | |
DKGVKKQXPOIZMD
|
9.5 | IC50 | 3 | — | |
JVXAHOWOEKOGPU
|
9.5 | IC50 | 2 | — | |
KLBQEMTZKYSAER
|
9.5 | IC50 | 3 | — | |
RRBZGDINLXZGOF
|
9.5 | Ki | 2 | — | |
ITCPHICQZLTGMF
|
9.5 | Ki | 2 | — | |
NWHXHTQTESHVJT
|
9.5 | IC50 | 3 | — | |
ZDYYEIJLRMPBFE
|
9.5 | IC50 | 2 | — | |
VTZPAZFULIFFPW
|
9.5 | IC50 | 2 | — | |
XPSDBVZHYGJDST
|
9.5 | IC50 | 2 | — | |
INVXZIIHCKLVCZ
|
9.5 | IC50 | 2 | — | |
CBMXZSXTNWSDCO
|
9.4 | IC50 | 2 | — | |
ZLASBNFOQVWTOW
|
9.4 | Ki | 2 | — | |
BLFAIXPYVCRLSD
|
9.4 | IC50 | 3 | — | |
JGUNRXYNLMQUNZ
|
9.4 | IC50 | 2 | — | |
NUZKZLIMRUWBCW
|
9.4 | Ki | 2 | — | |
YWWSGKYAMVMIMB
|
9.4 | IC50 | 5 | — | |
ODKUJMMJYPRCMG
|
9.4 | IC50 | 2 | — | |
RLHVVFZFOUAZRI
|
9.4 | IC50 | 3 | — | |
YGAFBPOODGQZPO
|
9.4 | IC50 | 2 | — | |
ABOUWUWXUJHANF
|
9.4 | IC50 | 2 | — | |
FHOXICOTPQTJOQ
|
9.4 | pIC50 | 6 | Yes | |
KAAMQZKICBFHHV
|
9.4 | IC50 | 3 | — | |
NTCZAFQHMWRHDH
|
9.4 | IC50 | 3 | — | |
OHKRUKRKVNWNNT
|
9.4 | IC50 | 3 | — | |
SUUMWGNYUOCOLH
|
9.4 | IC50 | 2 | — | |
XKQWUBPQPZBRPQ
|
9.4 | IC50 | 2 | — | |
XTHMHKVQVQAVJS
|
9.4 | IC50 | 3 | — | |
CWSCKWGKRCMORG
|
9.4 | Ki | 2 | — | |
LHLRTOZIMJUPET
|
9.4 | IC50 | 6 | — | |
FGHCWWRKFHRERP
|
9.4 | IC50 | 2 | — | |
WXUUCRLKXQMWRY
|
9.4 | IC50 | 5 | — | |
OSEKXTTWKHKJPC
|
9.4 | IC50 | 3 | — | |
BOCKHNDSVLBIHB
|
9.4 | IC50 | 2 | — | |
SBCMKKFTXRBACH
|
9.4 | IC50 | 3 | — | |
DCTZFRMQHDYKOF
|
9.3 | Ki | 2 | — | |
DVKPXBYBGGHAJZ
|
9.3 | IC50 | 2 | — | |
HMFRTKWUEKZJKW
|
9.3 | IC50 | 2 | — |